Investments
50Portfolio Exits
18Funds
5About Altitude Life Science Ventures
Altitude Life Science Ventures seeks opportunities to invest in early stage life science companies within markets with significant demand and growth potential, and then backs the highest-quality teams in those markets to build defensible, strong, and long-term businesses. At Altitude, our scope of investment opportunities extends beyond prescription drugs to any commercial application of proprietary technology that originates from a key advance in biology or chemistry.
Altitude Life Science Ventures Headquarter Location
1014 Market St., Suite 200
Kirkland, Washington, 98033,
United States
650-843-5000
Latest Altitude Life Science Ventures News
Apr 21, 2022
US biotech firm Tessera Therapeutics, which is pioneering a new approach in genetic medicine known as GENE WRITING technology, has raised over $300 million in Series C financing. Investors included a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA); Alaska Permanent Fund Corporation; Altitude Life Science Ventures; ARTIS Ventures; Cormorant Asset Management; Tessera’s founder, Flagship Pioneering; Hanwha Impact Partners; Longevity… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
Altitude Life Science Ventures Investments
50 Investments
Altitude Life Science Ventures has made 50 investments. Their latest investment was in Tessera Therapeutics as part of their Series C on April 4, 2022.
Altitude Life Science Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/19/2022 | Series C | Tessera Therapeutics | $300M | No | 3 | |
4/11/2022 | Series A | Ansa Biotechnologies | $68M | Yes | 4 | |
11/18/2021 | Series B | Generate Biomedicines | $370M | Yes | 15 | |
10/26/2021 | Series A | |||||
7/28/2021 | Series B |
Date | 4/19/2022 | 4/11/2022 | 11/18/2021 | 10/26/2021 | 7/28/2021 |
|---|---|---|---|---|---|
Round | Series C | Series A | Series B | Series A | Series B |
Company | Tessera Therapeutics | Ansa Biotechnologies | Generate Biomedicines | ||
Amount | $300M | $68M | $370M | ||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 3 | 4 | 15 |
Altitude Life Science Ventures Portfolio Exits
18 Portfolio Exits
Altitude Life Science Ventures has 18 portfolio exits. Their latest portfolio exit was DiCE Molecules Holdings on September 15, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
9/15/2021 | IPO | Public | 3 | ||
8/5/2021 | Acquired | 13 | |||
7/20/2021 | Acquired | 7 | |||
Date | 9/15/2021 | 8/5/2021 | 7/20/2021 | ||
|---|---|---|---|---|---|
Exit | IPO | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 3 | 13 | 7 |
Altitude Life Science Ventures Fund History
5 Fund Histories
Altitude Life Science Ventures has 5 funds, including Altitude Life Science Ventures Side Fund III.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
1/22/2019 | Altitude Life Science Ventures Side Fund III | $50M | 1 | ||
3/19/2018 | Altitude Life Science Ventures III | ||||
4/28/2015 | Altitude Life Science Ventures II | ||||
4/27/2015 | Altitude Life Science Ventures Fund II | ||||
Altitude Life Science Ventures Fund IV |
Closing Date | 1/22/2019 | 3/19/2018 | 4/28/2015 | 4/27/2015 | |
|---|---|---|---|---|---|
Fund | Altitude Life Science Ventures Side Fund III | Altitude Life Science Ventures III | Altitude Life Science Ventures II | Altitude Life Science Ventures Fund II | Altitude Life Science Ventures Fund IV |
Fund Type | |||||
Status | |||||
Amount | $50M | ||||
Sources | 1 |
Altitude Life Science Ventures Team
1 Team Member
Altitude Life Science Ventures has 1 team member, including current Founder, David Maki.
Name | Work History | Title | Status |
|---|---|---|---|
David Maki | Founder | Current |
Name | David Maki |
|---|---|
Work History | |
Title | Founder |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.